Strategies of Tumor Immune Evasion
- 1 January 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in BioDrugs
- Vol. 19 (6), 347-354
- https://doi.org/10.2165/00063030-200519060-00002
Abstract
During the last decade, increased understanding of the molecular mechanisms responsible for immune activation to protect against challenges by tumor cells has revolutionized the field of immunotherapy research. It has been demonstrated that the dysfunction of the host’s immune system represents one of the major mechanisms by which tumors evade immunosurveillance. This is due, for example, to T cell anergy, the existence of regulatory T cells, and systemic defects of dendritic cells derived from tumor patients. In addition, escape from immunosurveillance can also be linked to tumor-related factors, including secretion of immunosuppressive cytokines, resistance to apoptosis, and deficient expression of immunomodulatory molecules and major histocompatibility complex (MHC) class I antigens possibly due to immunoselection. Both host- and tumor-related mechanisms can lead to a failure to mount a proper anti-tumor-specific immune response, and these are frequently key factors in limiting the success of cancer immunotherapy.Keywords
This publication has 22 references indexed in Scilit:
- Structural and kinetic basis for heightened immunogenicity of T cell vaccinesThe Journal of Experimental Medicine, 2005
- Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking ToleranceJournal of Clinical Oncology, 2004
- Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic CellsJournal of Clinical Oncology, 2003
- Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical reportEuropean Journal Of Cancer, 2003
- Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant.Journal of Clinical Immunology, 2003
- Adoptive T cell therapy using antigen-specific CD8+T cell clones for the treatment of patients with metastatic melanoma:In vivopersistence, migration, and antitumor effect of transferred T cellsProceedings of the National Academy of Sciences, 2002
- Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic CellsThe Journal of Experimental Medicine, 2002
- The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunityTrends in Immunology, 2001
- Importance of CD4+ T helper cell responses in tumor immunityImmunology Letters, 2000
- Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor AntigenPublished by The American Association of Immunologists ,2000